

Mohamed Elmeliegy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7097408/publications.pdf>

Version: 2024-02-01

9
papers

246
citations

1306789

7
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

343
citing authors

#	ARTICLE	IF	CITATIONS
1	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	1.1	28
2	Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 105-115.	1.0	19
3	Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents. <i>Clinical Pharmacokinetics</i> , 2021, 60, 563-567.	1.6	9
4	Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, , .	2.3	3
5	Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 325-337.	1.1	4
6	Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations in the EMBRACA and ABRAZO Trials. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1334-1343.	1.0	12
7	Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations in the EMBRACA Trial. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1324-1333.	1.0	10
8	Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 699-714.	1.6	150
9	Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5076-5076.	0.8	11